1-5 of 5 results for subject:Palbociclib
Librarians' tools
- Search time
- 0.195 seconds
- Solr query time
- 0.001 seconds
- Search query
- subject:Palbociclib
- We searched for
- subject_t:Palbociclib OR subject_t:Ibrance OR subject_ses:434317
Type
House
Session
Year
Department
Member
Primary member
Answering member
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Health, what the current availability of palbociclib is on the NHS; and what steps are being taken to ensure that all breast cancer patients who would benefit from that drug are able to access it.
To ask the Secretary of State for Health, what the current availability of palbociclib is on the NHS; and what steps are being taken to ensure that all breast cancer patients who would benefit from that drug are able to access it.
The National Institute for Health and Care Excellence are currently reviewing the evidence for palbociclib in combination with an aromatase inhibitor for treating hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer in adults. Their draft guidance was out to consultation until 24 February. Stakeholders were encouraged to respond to the consultation.
To ask the Secretary of State for Health, what meetings representatives from NICE (a) have had and (b) plan to have with Pfizer during the consultation period for palbociclib (Ibrance) since the publication of the draft guidance on that drug on 3 February 2017.
To ask the Secretary of State for Health, what meetings representatives from NICE (a) have had and (b) plan to have with Pfizer during the consultation period for palbociclib (Ibrance) since the publication of the draft guidance on that drug on 3 February 2017.
The National Institute for Health and Care Excellence has advised that a meeting with Pfizer to discuss the appraisal of palbociclib took place on 22 February 2017.
To ask the Secretary of State for Health, what discussions he has had with charities on the future of the drug palbociclib (Ibrance).
To ask the Secretary of State for Health, what discussions he has had with charities on the future of the drug palbociclib (Ibrance).
Through its technology appraisal programme, the National Institute for Health and Care Excellence (NICE) provides independent, evidence-based guidance for the National Health Service on whether drugs and treatments represent a clinically and cost effective use of NHS resources. NICE is currently appraising palbociclib in combination with an aromatase inhibitor for treating hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer in adults. NICE published its draft guidance on 3 February and stakeholders have until 24 February to comment on its draft recommendations. NICE expects to publish its final guidance in June 2017.
To ask the Secretary of State for Health, what recent discussions he has had with metastatic breast cancer patients on the future availability of the Ibrance form of the drug palbociclib.
To ask the Secretary of State for Health, what recent discussions he has had with metastatic breast cancer patients on the future availability of the Ibrance form of the drug palbociclib.
Through its technology appraisal programme, the National Institute for Health and Care Excellence (NICE) provides independent, evidence-based guidance for the National Health Service on whether drugs and treatments represent a clinically and cost effective use of NHS resources. NICE is currently appraising palbociclib in combination with an aromatase inhibitor for treating hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer in adults. NICE published its draft guidance on 3 February and stakeholders have until 24 February to comment on its draft recommendations. NICE expects to publish its final guidance in June 2017.
To ask the Secretary of State for Health, if he will take steps to ensure that palbociclib is made available to all eligible breast cancer patients.
To ask the Secretary of State for Health, if he will take steps to ensure that palbociclib is made available to all eligible breast cancer patients.
Through its technology appraisal programme, the National Institute for Health and Care Excellence (NICE) provides independent, evidence-based guidance for the National Health Service on whether drugs and treatments represent a clinically and cost effective use of NHS resources. NICE is currently appraising Palbociclib in combination with an aromatase inhibitor for treating hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer in adults. NICE published its draft guidance on 3 February and stakeholders have until 24 February to comment on its draft recommendations. NICE expects to publish its final guidance in June 2017.